Eli Lilly and Company

Lilly to Participate in Cantor Fitzgerald Virtual Global Healthcare Conference

Friday, September 11, 2020 - 8:00pm

INDIANAPOLIS, Sept. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020.

Key Points: 
  • INDIANAPOLIS, Sept. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020.
  • Joshua Smiley, senior vice president and Lilly's chief financial officer, will participate in a virtual fireside chat at 8:40a.m., Eastern Time.
  • A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations .
  • Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.

Lilly to Participate in Morgan Stanley Global Healthcare Conference

Friday, September 11, 2020 - 5:00pm

INDIANAPOLIS, Sept. 11, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, September 16, 2020.

Key Points: 
  • INDIANAPOLIS, Sept. 11, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, September 16, 2020.
  • Joshua Smiley, senior vice president and Lilly's chief financial officer, will participate in a virtual fireside chat at 3:30p.m., Eastern Time.
  • A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations .
  • Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.

Lilly Announces Webcast to Discuss ESMO 2020 Presentations

Thursday, September 10, 2020 - 9:30pm

INDIANAPOLIS, Sept. 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 21, 2020 to discuss the company's presentations at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress.

Key Points: 
  • INDIANAPOLIS, Sept. 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 21, 2020 to discuss the company's presentations at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress.
  • The webcast will begin at 3:00 p.m. Eastern Daylight Time.
  • Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations .
  • Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.

Lilly Oncology to Showcase New Data from Robust Cancer Research Pipeline at ESMO Virtual Congress 2020

Thursday, September 10, 2020 - 11:45am

INDIANAPOLIS, Sept. 10, 2020 /PRNewswire/ --Data from 20 studies across Eli Lilly and Company's (NYSE: LLY) oncology product portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress, September 19-21, 2020.

Key Points: 
  • INDIANAPOLIS, Sept. 10, 2020 /PRNewswire/ --Data from 20 studies across Eli Lilly and Company's (NYSE: LLY) oncology product portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress, September 19-21, 2020.
  • Lilly continues to investigate Verzenio across the breast cancer continuum, which has now shown positive results in people with high risk HR+, HER2- early breast cancer.
  • During ESMO, Lilly will feature data from the RELAY trial looking at outcomes by EGFR mutation type in previously untreated EGFR-mutated metastatic NSCLC patients.
  • Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world.

CoastalSouth Bancshares, Inc. Completes $15 Million Subordinated Notes Offering

Wednesday, September 9, 2020 - 11:58pm

CoastalSouth intends to use the net proceeds from the Private Placement for general corporate purposes, including continued growth and maintenance of bank level regulatory capital ratios.

Key Points: 
  • CoastalSouth intends to use the net proceeds from the Private Placement for general corporate purposes, including continued growth and maintenance of bank level regulatory capital ratios.
  • The Notes have been structured to qualify as Tier 2 capital forregulatory capital purposes.
  • Alston & Bird LLP served as legal counsel toCoastalSouthandTroutman Pepper Hamilton Sanders LLPserved as legal counsel to the placement agent.
  • Established in 2003, CoastalSouth Bancshares, Inc. (OTCQX: COSO), a Virginia corporation, is headquartered in Hilton Head Island, South Carolina.

Fountain Therapeutics Moves Corporate Headquarters to Lilly Gateway Labs in South San Francisco

Wednesday, September 9, 2020 - 2:30pm

SAN FRANCISCO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fountain Therapeutics (Fountain), a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, today announced it has moved its corporate headquarters to Lilly Gateway Labs in South San Francisco upon selection by Eli Lilly and Company.

Key Points: 
  • SAN FRANCISCO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fountain Therapeutics (Fountain), a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, today announced it has moved its corporate headquarters to Lilly Gateway Labs in South San Francisco upon selection by Eli Lilly and Company.
  • We are honored to have been selected as one of the Bay Area companies to join Lillys first shared innovation laboratory, said John Dimos, Ph.D., chief executive officer of Fountain Therapeutics.
  • Julie Gilmore, Ph.D., site head and chief operations officer of Lilly Gateway Labs, added, We opened Lilly Gateway Labs with the goal of speeding the discovery of innovative medicines.
  • Fountain Therapeutics is a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age.

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

Monday, August 31, 2020 - 10:00am

Terns Pharmaceuticals, Inc., a biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat liver disease, today announced that the Companys management team will present at two upcoming investor conferences.

Key Points: 
  • Terns Pharmaceuticals, Inc., a biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat liver disease, today announced that the Companys management team will present at two upcoming investor conferences.
  • Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat liver disease including a pipeline of orally administered drug candidates for the treatment of non-alcoholic steatohepatitis (NASH).
  • Terns announced in July 2020 positive Phase 1 clinical data for its highly-selective SSAO inhibitor, TERN-201, demonstrating potent and sustained target engagement.
  • Terns investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.

Biosero Webinar: Integrating Laboratory Automation Software for Data-Driven Decision Making

Tuesday, August 25, 2020 - 4:00pm

Biosero and its customer Eli Lilly and Company invite pharmaceutical and biotech executives, laboratory managers, scientists, researchers and automation engineers to the webinar, "Actionable Insight into Your Automation Data with Green Button Go Software," Thursday, September 17, 2020, at 11 a.m. EST.

Key Points: 
  • Biosero and its customer Eli Lilly and Company invite pharmaceutical and biotech executives, laboratory managers, scientists, researchers and automation engineers to the webinar, "Actionable Insight into Your Automation Data with Green Button Go Software," Thursday, September 17, 2020, at 11 a.m. EST.
  • Ryan Bernhardt, Discovery Automation Group Leader, and Kahveh Saramout, Senior Robotic Applications Engineer, from Eli Lilly and Company will share how the pharmaceutical company leverages Green Button Go Automation Scheduling Software to streamline laboratory performance and data analytics.
  • "When labs use automation, they can gather, synthesize and analyze data more quickly and use it to make better decisions."
  • Biosero, Inc. develops automation software people use to make better decisions, in less time, using more data.

Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement

Tuesday, August 18, 2020 - 11:30am

"We are thrilled to expand on our successful China TYVYT collaboration with Lilly to now include markets outside of China.

Key Points: 
  • "We are thrilled to expand on our successful China TYVYT collaboration with Lilly to now include markets outside of China.
  • TYVYT (sintilimab injection) is an innovative drug with global quality standards jointly developed by Innovent and Lilly in China.
  • Under the agreement, Innovent and Lilly are co-developing and commercializing oncology medicines, including TYVYT (sintilimab injection) in China.
  • In August 2019, Innovent entered into an additional licensing agreement with Lilly to develop and commercialize a potentially global best-in-class diabetes medicine in China.

Innovent and Lilly Announce Expansion of TYVYT® (Sintilimab Injection) Licensing Agreement

Tuesday, August 18, 2020 - 11:30am

TYVYT (sintilimab injection) is an innovative drug with global quality standards jointly developed by Innovent and Lilly in China.

Key Points: 
  • TYVYT (sintilimab injection) is an innovative drug with global quality standards jointly developed by Innovent and Lilly in China.
  • Under the agreement, Innovent and Lilly are co-developing and commercializing oncology medicines, including TYVYT (sintilimab injection) in China.
  • In August 2019, Innovent entered into an additional licensing agreement with Lilly to develop and commercialize a potentially global best-in-class diabetes medicine in China.
  • In August 2020, Innovent and Lilly announced an expansion of their strategic alliance for TYVYT.